Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.34 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13029 | 0.88 | CYP3A4 (0.50) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Lithium SCHEMBL31361451 | 0.86 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Potassium SCHEMBL31361438 | 0.86 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL31361467 | 0.86 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Bromide SCHEMBL4668136 | 0.86 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL1879308 | 0.82 | TDP1 (0.56) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL189947 | 0.81 | CYP3A4 (0.38) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL11744136 | 0.81 | CYP3A4 (0.65) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL29375214 | 0.81 | CYP3A4 (0.38) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL15174010 | 0.77 | CA9 (0.41) | CYP3A4TSHRTDP1GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-06-05 | — | — | US | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| CN-119768400-A | Fused ring compound, application thereof and pharmaceutical composition containing fused ring compound | 苏州信诺维医药科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119698416-A | Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors | 英特莱治疗公司 | 2025-03-25 | — | — | CN | disclosed |
| US-7956222-B2 | Methods for producing dibromofluorobenzene derivatives | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956222-B2 | Methods for producing dibromofluorobenzene derivatives | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7807068-B2 | reacting 4-halo-2,6-difluorophenol with protecting group, dehalogenating to form protected phenol ether group, reacting with boronic acid/ester, coupling in presence of catalyst, deblocking, etherifying, esterifying; for optical, electro-optical and electronic use, liquid-crystal media and displays | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807068-B2 | reacting 4-halo-2,6-difluorophenol with protecting group, dehalogenating to form protected phenol ether group, reacting with boronic acid/ester, coupling in presence of catalyst, deblocking, etherifying, esterifying; for optical, electro-optical and electronic use, liquid-crystal media and displays | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20090141215-A1 | POLYMERIZABLE COMPOUNDS | MERCK PATENT GESELLSCHAFT (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090141215-A1 | POLYMERIZABLE COMPOUNDS | MERCK PATENT GESELLSCHAFT (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080045753-A1 | Methods For Producing Dibromofluorobenzene Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20080045753-A1 | Methods For Producing Dibromofluorobenzene Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20080045753-A1 | Methods For Producing Dibromofluorobenzene Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1780192-A1 | METHOD FOR PRODUCING DIBROMOFLUOROBENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | CYP3A4 284/4885TSHR 362/4885TDP1 1626/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | CYP3A4 4126/4885TSHR 2326/4885TDP1 3466/4885 |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | SLC2A9, SLC2A1, SLC2A8 | CYP3A4 3056/4885TSHR 3179/4885TDP1 2394/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | CYP3A4 2289/4885TSHR 3470/4885TDP1 2259/4885 |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | CYP3A4 2128/4885TSHR 3163/4885TDP1 3674/4885 |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | CYP3A4 2868/4885TSHR 2854/4885TDP1 938/4885 |
| US-20090141215-A1 | POLYMERIZABLE COMPOUNDS | VCL, LCP1, LPXN | CYP3A4 3971/4885TSHR 4880/4885TDP1 3198/4885 |
| US-20080045753-A1 | Methods For Producing Dibromofluorobenzene Derivatives | CYP2F1, BLVRB, CBR1 | CYP3A4 148/4885TSHR 1979/4885TDP1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.